iwMyeloma 2022 | An insight into the MMRF-CoMMpass study
Jonathan Keats
• 26 Mar 2022
Jonathan Keats, PhD, Translational Genomics Research Institute, Phoenix, AZ, shares some updates from the MMRF-CoMMpass study (NCT01454297) and the importance of this research in allowing clinicians to better understand high-risk disease. Dr Keats first highlights the data collection protocol used in this study, and the important role that this data will play in myeloma treatment. Dr Keats then discusses genomic features associated with high-risk and ultra high-risk disease, including p53 mutation, gain of chromosome 1q, and the important prognostic value of these genomic aberrations in patients with myeloma. This interview took place at The International Workshop on Myeloma 2022, held in Scottsdale, AZ.
